Protein Sciences' FluBlOk meets Phase II/III endpoint

In a U.S. Phase II/III trial, Protein Sciences' FluBlOk prophylactic flu vaccine met the primary endpoints of safety and at least a four-fold increase in antibody titers in 460 healthy volunteers, age...